中恒集团持续加大研发投入。2021年至2024年，中恒集团所属企业研发投入总额达6.04亿元，占营业收 入的5.37%。2023年，中恒集团通过逐步建立研发经费拨付机制与落实研发投入视同利润加回、关键技 术研发双倍加回等考核方式为研发投入提供稳定保障。 近5年来，中恒集团开展科创项目80余项，1类创新药立项6个，其中"三芪颗粒"为公司10年来首个获批 Ⅱ、Ⅲ期临床试验的中药1类新药；全球独家品种注射用去水卫矛醇成功上市，被纳入《胶质瘤化疗中 国专家共识(2024)》，为胶质瘤患者带来了新的治疗选择与健康希望；注射用血栓通(冻干)、中华跌打 丸、肝得乐等产品新适应症、新剂型研究，取得阶段性突破；研发大健康产品新品341个，已投产上市 114个，产值超2亿元；48个专利获得授权。 此次中恒集团引进的慢性心衰创新药为化药1.1类创新药，该药物靶向心肌能量代谢调节机制，直击当 前慢性心衰治疗领域未被满足的临床需求。引进该项目是中恒集团围绕核心疾病领域进行前瞻性、系统 性战略布局的关键落子，与集团现有产品形成强大的协同效应。 值得一提的是，早在今年4月，中恒集团中药1.1类创新药"三芪颗粒"正式获得国家药品监督管理局的 ...

Core Viewpoint - Zhongheng Group has acquired a patented technology for a new drug to treat chronic heart failure, indicating a strategic move to enhance its product line and market competitiveness [1] Group 1: Acquisition Details - Zhongheng Group's subsidiary, Zhongheng Innovation, has purchased a drug technology for chronic heart failure for RMB 55 million [1] - The acquired drug is a Class 1 innovative chemical drug that addresses energy metabolism disorders in myocardial cells, offering a new treatment pathway [1] - There are currently no similar mechanism products available in the domestic and international markets [1] Group 2: Strategic Implications - The acquisition aligns with Zhongheng Group's strategic focus on unmet clinical needs and potential markets, particularly in cardiovascular, metabolic, and autoimmune diseases [1] - The company aims to enhance its business and product line through this acquisition, thereby increasing its market competitiveness [1] - Zhongheng Group is building a differentiated competitive advantage in cardiovascular treatment by leveraging a dual-driven model of independent R&D and strategic acquisitions [1]

Group 1 - Niuwei Co., Ltd. reported a net profit of 637 million yuan for the first half of 2025, representing a year-on-year increase of 30.47% [1] - The company achieved a total operating revenue of 3.404 billion yuan, up 19.96% year-on-year [1] - Niuwei specializes in the research, manufacturing, and sales of industrial valves [2] Group 2 - Shandong Haohua plans to acquire a 29% stake in Zhongyan Alkali Industry with a total investment of 2.32 billion yuan [2] - The company is involved in the production of soda ash and caustic soda [3] Group 3 - Dongfang Co., Ltd. announced a partnership with Dongfang Import and Export Company to develop overseas marketing business [38] - The company focuses on the research, production, and sales of light commercial vehicles and powertrains [38] Group 4 - Xinyuan Technology reported a net profit of 52.6 million yuan for the first half of 2025, a year-on-year increase of 10.70% [12] - The company achieved an operating revenue of 2.871 billion yuan, up 3.86% year-on-year [12] - Xinyuan provides one-stop custom development and production services for pharmaceutical companies and research institutions [12] Group 5 - Zhuhai Piano announced that its subsidiary won the operating rights project for the Baihuazhai scenic area, with an investment of no less than 400 million yuan over 20 years [21] - The company specializes in the research, manufacturing, and sales of pianos and digital musical instruments [21] Group 6 - Zhenghong Technology reported a sales revenue of 26.02 million yuan from pig sales in July, a year-on-year increase of 288.69% [16] - The company sold 63,000 pigs in total from January to July 2025, with a cumulative sales revenue of 109 million yuan, representing a year-on-year increase of 38.06% [16] - Zhenghong focuses on feed products and pig farming [17] Group 7 - ST Nuotai received the cGMP certification from Brazil's National Health Surveillance Agency for its production facility [15] - The company specializes in the research and development of peptide drugs and small molecule pharmaceuticals [15] Group 8 - Guizhou Moutai has repurchased a total of 3.4517 million shares, accounting for 0.2748% of its total share capital, with a total expenditure of 5.301 billion yuan [48][49] - The company is engaged in the production and sales of Moutai liquor and related products [49]

Group 1 - The Helicobacter pylori concept sector declined by 0.50%, ranking among the top declines in concept sectors, with notable declines in stocks such as Keta Bio, Anglikang, and Asia-Pacific Pharmaceutical [1][2] - Among the 49 stocks in the Helicobacter pylori concept sector, 27 stocks saw price increases, with Zhongheng Group, Hanyu Pharmaceutical, and *ST Sansheng leading the gains at 9.85%, 5.63%, and 5.05% respectively [1][4] - The Helicobacter pylori concept sector experienced a net outflow of 1.725 billion yuan in main funds, with Hanyu Pharmaceutical seeing the largest outflow of 909.33 million yuan [2][3] Group 2 - The top gainers in the concept sectors included the Armament Reorganization concept at 6.12%, PEEK materials at 4.11%, and Brain-Computer Interface at 2.72% [2] - The main funds saw inflows in stocks such as Zhongheng Group, Baicheng Pharmaceutical, and Asia Treasure Pharmaceutical, with inflows of 88.23 million yuan, 63.86 million yuan, and 19.51 million yuan respectively [2][4] - The stocks with the largest net outflows in the Helicobacter pylori concept included Asia-Pacific Pharmaceutical at -8.16%, Keta Bio at -10.28%, and Anglikang at -9.46% [2][3]

今日涨跌幅居前的概念板块 截至8月5日收盘，仿制药一致性评价概念下跌0.55%，位居概念板块跌幅榜前列，板块内，昂利康、亚 太药业、南新制药等跌幅居前，股价上涨的有46只，涨幅居前的有诚意药业、桂林三金、中恒集团等， 分别上涨10.04%、10.00%、9.85%。 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 兵装重组概念 | 6.12 | 华为盘古 | -0.78 | | PEEK材料 | 4.11 | 仿制药一致性评价 | -0.55 | | 脑机接口 | 2.72 | Sora概念(文生视频) | -0.53 | | 铜缆高速连接 | 2.60 | 流感 | -0.50 | | 汽车热管理 | 1.89 | 幽门螺杆菌概念 | -0.50 | | 碳纤维 | 1.76 | 智谱AI | -0.48 | | 高压氧舱 | 1.76 | 创新药 | -0.46 | | 卫星导航 | 1.76 | 辅助生殖 | -0.44 | | 液冷服务器 | 1.75 | 肝炎概念 | -0.38 | | 成飞概念 | 1.74 | MLOp ...

Group 1 - As of August 4, 2025, Zhongheng Group's stock price is 2.74 yuan, down 0.02 yuan or 0.72% from the previous trading day [1] - The trading volume for the day was 616,400 hands, with a total transaction amount of 166.7 million yuan [1] - Zhongheng Group primarily engages in pharmaceutical manufacturing, with core products including thrombolytic agents for cardiovascular diseases [1] Group 2 - The company has a wholly-owned subsidiary, Zhongheng Innovation, which acquired a patent for a drug treating chronic heart failure for 55 million yuan [1] - This drug is a novel compound discovered by the Navy Medical University, significantly enhancing myocardial energy metabolism, and currently, there are no similar drugs on the market globally [1] - The company operates in various sectors, including pharmaceutical manufacturing, research and development, and health food, making it a key player in the Guangxi region [1]

格隆汇8月4日丨中恒集团(600252.SH)公布，为契合公司发展战略，持续优化与延伸产品管线，公司全 资子公司中恒创新拟受让取得中国人民解放军海军军医大学持有的一种治疗慢性心力衰竭的药物技术 （专利权）。根据上海技术交易所2025年5月20日发布的挂牌公告，该项目挂牌转让底价为人民币 5,500.00万元，保证金为人民币50.00万元，本次转让挂牌结束日期为2025年6月18日。该项目的转让总 价由首付款与里程碑付款构成。其中，首付款不少于500.00万元，需于《技术（专利权）转让合同》生 效之日起10个工作日内支付至转让方指定银行账户，后续里程碑付款在相对应的里程碑事件发生后10个 工作日内予以支付；具体节点与条件以合同约定为准。2025年6月20日，中恒创新收到上海技术交易所 出具的《受让资格确认通知书》《组织签约通知》，确认中恒创新为"一种治疗慢性心力衰竭的药物"的 受让方。成交价格为人民币5,500.00万元。2025年8月1日，中恒创新与中国融通科研院签订《技术（专 利权）转让合同》。 ...

广西梧州中恒集团股份有限公司 关于全资子公司受让取得一种治疗慢性心力衰竭的 药物技术（专利权）并签署《技术（专利权）转让 合同》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600252 证券简称：中恒集团 公告编号：临 2025-72 ● 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）的 全资子公司广西中恒创新医药研究有限公司（以下简称"中恒创新"）以受让方 式取得中国融通科学研究院集团有限公司（以下简称"中国融通科研院"）在上 海技术交易所公开挂牌转让的一种治疗慢性心力衰竭的药物技术（专利权），交 易价格为人民币 5,500.00 万元（不含税，下同）。 2025 年 6 月 20 日，中恒创新收到上海技术交易所出具的《受让资格确认通 知书》《组织签约通知》，确认中恒创新为"一种治疗慢性心力衰竭的药物"的 受让方。成交价格为人民币 5,500.00 万元。 ● 本次交易不构成关联交易，也不构成重大资产重组。 ● 本次交易已经公司第十届董事会第二十九次会议审议通过，无需提交 ...

Group 1 - The company provided a guarantee for its subsidiary, Shuangqian Industry, to support its daily operations and business development needs, with a maximum guarantee amount of RMB 19 million [1][4] - The guarantee was approved during the company's board meeting and annual shareholders' meeting, allowing for a total credit limit of up to RMB 5 billion for 2025, with a maximum guarantee amount of RMB 2.5 billion [2][5] - The company has a total external guarantee balance of RMB 401.82 million, which is 6.67% of its audited net assets for 2024, with no overdue guarantees reported [7] Group 2 - The company initiated a share repurchase plan, allowing for the buyback of shares at a price not exceeding RMB 3.80 per share, with a total repurchase amount between RMB 300 million and RMB 500 million [11] - As of July 31, 2025, the company had repurchased a total of 109.86 million shares, representing 3.32% of its total share capital, with a total payment of approximately RMB 277.30 million [12] - The company will continue to comply with relevant regulations and disclose progress on the share repurchase in a timely manner [13]

Group 1 - The company announced that as of July 31, 2025, it has repurchased a total of 109,860,897 shares through the Shanghai Stock Exchange trading system, representing 3.3157% of its total share capital of 3,313,345,567 shares [2]